DelveInsight, a leading market research and consulting firm, has recently published an in-depth report on the Achromatopsia Pipeline, providing valuable insights into emerging therapies, companies, and future outlooks.
DelveInsight’s, “Achromatopsia Pipeline Insight 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Achromatopsia pipeline landscape. It covers the Achromatopsia pipeline drug profiles, including Achromatopsia clinical trials and nonclinical stage products. It also covers the Achromatopsia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the Achromatopsia Pipeline treatment landscape of the report, click here @ Achromatopsia Pipeline Outlook
Key Takeaways from the Achromatopsia Pipeline Report
For further information, refer to the detailed Achromatopsia Unmet Needs, Achromatopsia Market Drivers, and Achromatopsia Market Barriers, click here for Achromatopsia Ongoing Clinical Trial Analysis
Achromatopsia Overview
Achromatopsia is characterized by reduced visual acuity, pendular nystagmus, increased sensitivity to light (photophobia), a small central scotoma, eccentric fixation, and reduced or complete loss of color discrimination. All individuals with achromatopsia (achromats) have impaired color discrimination along all three axes of color vision corresponding to the three cone classes: the protan or long-wavelength-sensitive cone axis (red), the deutan or middle-wavelength-sensitive cone axis (green), and the tritan or short-wavelength-sensitive cone axis (blue).
Request a sample and discover the recent advances in Achromatopsia Ongoing Clinical Trial Analysis and Medications, click here @ Achromatopsia Treatment Landscape
Achromatopsia Emerging Drugs
AAV-CNGA3, gene therapy candidate designed to restore cone function, are delivered via subretinal injection to the area of the eye where most of the cones in the retina are located. Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases. Under the terms of the agreement, MeiraGTx to grant Janssen an exclusive worldwide license to certain clinical assets in MeiraGTx’s inherited retinal disease portfolio. The companies have also formed a research collaboration to develop a pipeline of products addressing novel gene targets, giving Janssen the exclusive option to license new treatments for other inherited retinal diseases.
Dive deep into rich insights for drugs for Achromatopsia Market Drivers and Achromatopsia Market Barriers, click here @ Achromatopsia Unmet Needs and Analyst Views
Achromatopsia Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for Achromatopsia. The companies which have their Achromatopsia drug candidates in the most advanced stage, i.e. Phase I/II include, Janssen Pharmaceutical.
Scope of the Achromatopsia Pipeline Report
Got Queries? Find out the related information on Achromatopsia Mergers and acquisitions, Achromatopsia Licensing Activities @ Achromatopsia Emerging Drugs, and Recent Trends
Table of Content
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting-services